what is known already: Phthalates are anti-androgenic environmental agents known to alter early development, with possible effects on pubertal onset. study design, size, and duration: This multi-ethnic study included 1239 girls from New York City, greater Cincinnati, and the San Francisco Bay Area who were 6-8 years old at enrollment (2004 -2007) and who were followed until 2011.
Introduction
During the past few decades, the age at which girls begin puberty has declined, including age at breast and pubic hair onset and age at menarche. Much interest has arisen about the possible role of environmental agents in relation to pubertal timing, with the expectation that development would be accelerated by estrogenic chemicals in females and by androgenic agents in males. Phthalate diesters are added to various products to improve performance of building materials, medical devices and personal products. Widespread exposure occurs from use of consumer products such as perfume or plastic tubing, from air volatization and from the diet. Phthalates are best known for their antiandrogenic potential that does not involve the androgen receptor. This research has found parallels in experimental and human research for impeding genital development and spermatogenesis (Hauser, 2008; Swan, 2008) . In female rats, phthalates exhibit both agonist and antagonist effects, suggesting that pubertal development might be accelerated or delayed depending on timing, dose and other factors (Grande et al., 2006) .
Developmental effects in humans that might arise from exposure to phthalates are of concern, as exposures to phthalates are universal, and the upper ranges of measured urinary biomarkers exceed micromolar concentrations, comparable to those that cause developmental delay in animals. Two reports have found later pubertal development with phthalate exposures among girls, in cross-sectional study designs including that from the cohort in this paper Frederiksen et al., 2012) , whereas analysis of general population data from the U.S. National Health and Nutrition Examination Survey found no relationship with menarche age (Buttke et al., 2012) . We have undertaken the first (to the best of our knowledge) longitudinal study of pubertal onset in girls in relation to phthalate exposures. The objective of this research was to investigate whether phthalate exposures were associated with pubertal timing in girls and whether these relationships were modified by obesity.
Methods

Subjects and outcomes
The Breast Cancer and Environment Research Program (BCERP) epidemiology project is a longitudinal study of girls enrolled at 6 -8 years of age who are being followed through puberty. Enrollment occurred at three sites from 2004 to 2007. Mount Sinai School of Medicine (MSSM) recruited in East Harlem in New York City; Cincinnati Children's Hospital (Cincinnati) recruited in the greater Cincinnati metropolitan area and through the Breast Cancer Registry of Greater Cincinnati and Kaiser Permanente Northern California (KPNC) recruited members of the KPNC Health Plan in the San Francisco Bay Area. Eligibility included age, female sex, no underlying endocrine medical conditions and at MSSM eligibility required black or Hispanic race/ethnicity. Protocols and urinary phthalate metabolite concentrations have been described previously .
Ethical approval
All sites obtained informed consent from parent or guardian, approved by the Institutional Review Boards at each institution and at the Centers for Disease Control and Prevention (CDC).
Data collection
A questionnaire was completed by the girl's caregiver (usually the mother) that included medical history, environmental exposures, demographic variables and race/ethnicity (Black, White, Asian and Hispanic or non-Hispanic). Weight, height, breast and pubic hair stages 1 -5 (PH1 -5) were measured at each visit using standardized protocols previously described , and urine was collected at baseline. Visits for MSSM and KPNC were annual and for Cincinnati were every 6 months through 2010, once in 2011. The main goal of BCERP was to examine determinants for age at first pubertal development (stage 2 versus stage 1 which is no development). Pubertal stages for breast (B1 -B5) and PH1-5 were determined by observation and palpation. A standardized written protocol with photographs of each stage was used to train and test examiners (van Wieringen et al., 1985; Biro et al., 2010) . Inter-rater assessments were performed at each site by one pediatrician who found 'substantial agreement' (kappa 0.67) and concordance (87%; 117/127) among 39 examiners . Age-and sex-specific body mass-index percentiles (BMI%) were calculated based on CDC growth charts (CDC, 2000) .
Urinary biomarker measurements
Samples (n ¼ 1170), collected at baseline, were analyzed at the National Center for Environmental Health laboratories at CDC for the nine phthalate metabolites most frequently detected in the US general population. These are monoethyl phthalate (MEP), mono-n-butyl phthalate (MBP), mono-isobutyl phthalate (MiBP), mono-benzyl phthalate (MBzP), mono-3-carboxypropyl phthalate (MCPP), mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono(2-ethyl-5-hydroxylhexyl) phthalate (MEHHP), mono (2-ethyl-5-oxohexyl) phthalate (MEOHP) and mono(2-ethylhexyl) phthalate (MEHP) (CDC, 2009) . Analytic and quality control procedures have been reported . We imputed values below the limit of detection (LOD) as LOD/ p 2. For the majority of phthalate biomarkers in our study, measurements were above the LOD (.98%), except for MEHP [80% .LOD; ], and thus imputation is unlikely to alter our findings (Lubin et al., 2004) . However, as methods of handling imputation have evolved over recent years, we examined results using MEHP values imputed with Helsel's robust probability plotting method for LODs (Helsel, 1990) . Results were almost identical to those reported in the tables for MEHP and molar sum of low-molecular weight phthalate metabolites (low-MWP). Normalization for urine dilution was accomplished by including log e -creatinine in models using continuous log-biomarker variables (log e -mg/l); for quintiles we used creatinine-corrected concentrations (mg/g creatinine) to create cut points. To ascertain whether results were affected by the method of adjusting for dilution, we determined that extreme metabolite concentrations were not due to creatinine concentration alone and that low creatinine values were distributed across the range of biomarker concentrations. Results reported in the tables using creatininecorrected or -adjusted urinary concentrations were not attenuated if low Phthalate exposure and puberty in girls creatinines were removed. Models using concentrations not creatininecorrected or -adjusted were very similar to those reported if low creatinines were excluded (,50 mg/dl). Further, we assessed concordance of quintile assignments for SDEHP, by comparing the frequency distribution of observations by mg/l cut points versus those by mg/g creatinine (kappa ¼ 0.36; for creatinine .50 mg/dl, kappa ¼ 0.48). As described in previous papers , we also combined the phthalate metabolites into groups that represent similar sources and similar biologic activity, low-(,250 dalton, low-MWP) and high-molecular weight (.250 dalton, molar sum of high-molecular weight phthalate metabolites, high-MWP) phthalate metabolites. High-MWP include the 4 di(2-ethylhexyl)phthalate (DEHP) metabolites (SDEHP; including MECPP, MEHHP, MEOHP and MEHP), MBzP and MCPP. Low-MWP include MEP, MBP and MiBP. We expressed low-MWP molar sum as MEP (molecular weight 194) and high-MWP (micromoles/l) as MEHP (molecular weight 278) so that units were the same as the single analytes (mg/l or mg/g creatinine).
Statistical analyses
We analyzed ages at breast and pubic hair stages, assessed at entry and in as many as 6 years of follow-up, in relation to urinary concentrations of phthalate metabolites and potential confounders to determine the relative risk of advancing from stage 1 to 2. Phthalate exposure biomarkers were analyzed as continuous variables and in addition as quintiles of concentration to evaluate the shape of the dose -response. To examine intercorrelations of the phthalate urinary metabolites, we computed the rank correlation coefficient (Spearman r S ) between the individual and total concentrations. Analyses were conducted using SAS (version 9.2.; SAS Institute, Inc.). We performed multivariable analyses using Cox proportional hazards models with Proc PHREG to compute hazard ratios (HR) and 95% confidence intervals (CIs) for age at development (breast stage 2 ¼ B2 or pubic hair stage 2 ¼ PH2) by exposure. HRs ,1 were interpreted as reduced risk of pubertal development or delayed pubertal onset, while HRs greater than one were interpreted as increased risk of pubertal development. For most girls, event age was the midpoint between the last stage 1 visit (with no earlier stage 2 exam) and the first stage 2 or higher visit (with no successive stage 1 visits; n ¼ 826 for B2, n ¼ 793 for PH2). Girls who were B2 (n ¼ 175) or PH2 (n ¼ 138) at entry were assigned event age as 6 months before enrollment; girls who did not achieve stage 2 (n ¼ 169 B1, n ¼ 234 PH1) were treated in the model as censored at the time of their last visit. Adjusted survival curves and PH2 median ages were predicted from the baseline survivor function of adjusted Cox models; quintiles of the phthalate biomarker concentrations were included in the strata statement (Allison, 2010) .
We evaluated potential confounders (those in Table I as well as height and season of urine collection (which might reflect different dietary intake patterns and indoor air concentrations) related to pubertal development and urinary biomarker concentrations using a conceptual model based on their biologic plausibility and correlations within the pathway. BMI% at the last puberty stage 1 visit (e.g. B1-BMI%) was chosen as a covariate in order to control for adiposity at a consistent time point within the cohort, because baseline was not equidistant from stages 2 for all participants. For girls who were B2 or PH2 at entry, baseline BMI% was used. We justified use of baseline BMI% by finding in a subset of girls that BMI% at the last B1-visit and the B2-visit were almost identical (Spearman r 0.94, n ¼ 598). In the same subset, B1-BMI% was imputed from B2-BMI% in models predicting B2-height [r 2 0.94] or B2-weight [r 2 0.92] adjusted for site and race; it was also very close to actual B1-BMI%. Variables that did not improve precision or alter the biomarker estimate by more than 10% were eliminated in a manual backward stepwise manner from the models; they were re-entered individually into the final model to verify model fit. Final models included child race/ ethnicity, caregiver education, BMI% and site. We also used quintiles of biomarkers to elucidate dose -response and influence of BMI on associations of phthalate biomarkers with pubertal onset. To evaluate linearity, we checked that estimates for continuous log e -biomarker variables were consistent with those using quintiles. We computed the P-trend of HRs across biomarker quintiles by substituting median biomarker concentrations of the quintiles (log e mg/g creatinine) as a continuous variable in the quintile models. We did not observe any trends for quintile models suggestive of a threshold response. For comparison, we examined results from Weibull accelerated failure models appropriate for interval censored longitudinal data using PROC LIFEREG; results were almost identical to Cox models. Because adiposity is a strong endogenous hormonal risk factor for pubertal development (Kaplowitz, 2008) , we examined possible exposure modification by BMI% (BMI dichotomized at the 85th-age-specific percentile: normal and overweight). To test interactions, we used the product of dichotomized BMI% times the biomarker variable (continuous or ordinal quintile values). We conducted other sensitivity analyses to understand potential confounders better, [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] N (total) ¼ 1170 girls with at least one biomarker (5 missing age at PH2, 1 missing PH1 BMI percentile (BMI%), 1 missing B1 BMI%, 28 missing education). All distributions differed by characteristics (P , 0.001) except for high MWP with BMI%. Adjusted geometric means differed by race/ethnicity, site. Low-/high-MWP, low-/high-molecular weight phthalate metabolites; mg/gC, mg/g creatinine.
as there were collinearity and unbalanced distributions among biomarker concentrations and covariates. To clarify associations within and between sites, we used a joint exposure-site variable combining three sites with tertiles of the molar sum of DEHP metabolite (SDEHP) concentrations (nine-level variable). The model was run three times in order to compare high versus low exposure estimates within a particular site, while retaining data from other sites, by changing the reference group to be the category, first SDEHP tertile-site. We also examined results stratified by site or race/ethnicity and by including height; models that included only girls with temporally consistent stages (e.g. stage B1 followed by B2, no successive stage B1, no girls without a B1-visit); with three or more visits. These analyses did not alter our findings.
Results
Characteristics of subjects and exposures
Girls were 6-8 years old at enrollment, and the proportions of Black, Hispanic, White race/ethnicities were similar, with few Asians (Table I ). Approximately 30% of girls were overweight or obese at baseline or at the last pubertal stage 1 visit (Table I) . Among 1170 girls with urinary biomarker results, the Kaplan -Meier estimate for median age at B2 was 112.5 months (CI 111.5-113) or 9.4 years; for median age at PH2 it was 119 months (CI 117.5-121) or 9.9 years (not shown).
The minimum ages for both B2 and PH2 were 67 months; the maxima were 156 months, which occurred for age at B2 and PH2 in the same girl (not shown). Phthalate urinary biomarker means varied by study characteristics as reported earlier , but when mutually adjusted for these factors, the means differed only by race/ethnicity and site (Table I ). In addition, low-MWP varied by season of urine collection [not shown, as it was not a confounder in final models; shown in ]. Phthalate urinary biomarker sums spanned a wide range of concentrations. Concentrations of the four DEHP metabolites were highly intercorrelated (r S 0.7-0.99, not shown). MBzP and MCPP had lower correlations with each other and with the other high-MWP biomarkers (r S 0.2-0.4). Low-MWP metabolites had correlations of 0.3-0.6 with each other. Correlations (r S ) of low-MWP with high-MWP or SDEHP were 0.3. These relationships are consistent with the phthalate exposures having come from similar environmental sources. Low-MWP and high-MWP concentrations were .150 mg/l (geometric means, Table I ). The 90th percentiles exceeded 2 micromolar (2.7 mM/g creatinine for low-MWP, 2.2 mM/g creatinine for high-MWP, respectively; not shown). Medians of high-MWP and SDEHP in the fifth and first quintiles approximated the 90th and 10th percentiles, respectively.
Associations of high-MWP exposures with age at puberty
High-MWP exposures including SDEHP and the constituent high-MWP metabolites were associated with later age at PH2 (Table II) . Risk estimates were similar for high-MWP and SDEHP. Reduced risk for PH2 was 8 -9% per log e -unit change (2.7-fold) in urinary metabolite concentrations. For the fifth versus first quintiles of SDEHP risk for PH2 was 20-30% lower, and the adjusted median age at PH2 was 8.5 months older (Table III) .
SDEHP-body size interactions and age at PH2
Later ages at PH2 appeared to be more linear across biomarker quintiles among normal-weight than overweight girls. For example, the risk (HRs) decreased with quintiles of SDEHP and older predicted ages at PH2 monotonically increased for normal-weight girls, P-trend 0.005 (Table III) . As seen in Fig. 1 , the association of SDEHP with adjusted age at PH2 was better in the normal-weight stratum than overweight. However, interaction terms for BMI% × SDEHP were not significant. Age at PH2 was 9.5 months later in the fifth than first quintile of SDEHP for normal-weight girls (adjusted); the difference was smaller for overweight girls (6.5 months; Fig. 1 , as estimated from data in Table III ). Comparing normal-weight with overweight girls within the same quintiles of SDEHP, age at PH2 was 8-12 months later, representing the BMI-effect (Table III and Fig. 1 ). High-MWP was not associated with age at B2. MBzP, a high-MWP constituent, was modestly associated with later age at B2 (P-trend ¼ 0.082 for continuous log e MBzP, Table II ); for the fifth versus first quintile of the biomarker the HR was 0.83 (CI 0.68 -1.02; P-trend 0.042, not shown). However, a similar linear association for MBzP with age at PH2 (P ¼ 0.022 for continuous log e -biomarker, Table II) Associations between low-MWP exposures and age at puberty Low-MWP was not associated with PH2-or B2-age after adjusting for covariates (Table II) . MBP (a low-MWP metabolite) showed a weak inverse association with age at PH2 as a continuous variable [ Table II , HR 0.92 (CI 0.85 -1.00)], but there was no association with age at PH2 in models using MBP quintiles; estimates and CIs all included the null, P-trend ¼ 0.107 (not shown). The range of concentrations for MBP was also narrower than for the molar sums, e.g. low-MWP, possibly limiting statistical power to detect an association.
Alternative explanations
The phthalate-PH2 associations were robust in various sensitivity analyses that attempted to examine alternative explanations and potential residual confounding. Excluding BMI%, which may be on the path between phthalate exposure and pubertal onset, changed neither estimates nor precision very much. As an example, for log e -high-MWP with age at PH2 risk was lower (HR 0.91, CI 0.84 -0.99, Table II); the HR was 0.92 (CI 0.84 -0.99) when BMI% was removed from the model. For low-MWP with age at PH2 the association was the same with or without BMI% [fully adjusted HR 0.97 (CI 0.90-1.05, Table II) ; without BMI% HR 0.99 (CI 0.91 -1.07, not shown)]. We were concerned that inclusion of site as a covariate in the models might over-adjust the estimates; the variability due to differences across study site populations is desirable, and in addition site was collinear with other covariates. In our results, excluding site only slightly altered either estimates or precision. For example, using the joint SDEHP tertile-site variable models for age-at-PH2 and rotating the reference group so that it was the first tertile for each site, we observed HRs that were 0.74 (CI 0.54 -1.01) for NYC, 0.82 (CI 0.63-1.07) for KPNC and 0.89 (CI 0.65 -1.22) for Cincinnati (third versus first tertile of SDEHP; joint tertile-site variable, P ¼ 0.028, not shown). Site-stratified models were similar but less precise (not shown). The P-interaction for SDEHP × site was 0.73. Models stratified by other factors did not materially alter the findings. In a previous report, similar to the findings we report now, we observed reduced risk of PH2 at the second annual visit with high-MWP [prevalence ratio (PR) 0.94 (CI 0.88 -1.00) for fifth versus first quintile, P-trend 0.04; . In the same report, earlier B2 and PH2 were seen with increasing low-MWP, though these positive associations were weak (PRs , 1.10, P-trend , 0.09).
Discussion
Our main finding is that in these girls, 10-fold higher exposures to high-MWP including DEHP, as estimated from the urinary concentrations of their metabolites, was associated with the transition from PH1 to PH2 being later by 8 months. In hazards models, this represented 20-30% decreased risk over a 10-fold range of exposure. Ages for both PH2 and B2 were younger with increasing low-MWP in unadjusted associations, but there were no effects on pubertal age in models controlled for confounders. Unadjusted associations of low-MWP with pubertal ages may be due to its strong correlation with BMI%; the correlation was poor for high-MWP (not shown). Although removing BMI% from adjusted models of low-MWP did not change the null associations, other covariates were correlated with BMI and might have served as its surrogate. Our hypothesis was that exposure effects should be more apparent in low-than high-BMI girls. Actual estimates of age at PH2 were not very different by BMI% strata for high-MWP and SDEHP metabolites, but the dose-response relationships were more apparent in normal-weight girls. Cox proportional hazard models included log e -urinary creatinine. Adjusted models further added child race, caregiver education, child BMI% and study site. N's differ because 5 girls had no pubic staging and/or missing covariates. Unadjusted models were similar when restricted to this number. Adjusted models excluding site, BMI%, or including height% had similar estimates and CI. High-MWP included SDEHP plus MCPP and MBzP.
a Low-/High-MWP, Low-/High-molecular weight metabolites; SDEHP, molar sum of di(2-ethylhexyl) phthalate metabolites; MECPP, mono-2-ethyl-5-carboxypentyl phthalate; MEHHP, mono(2-ethyl-5-hydroxylhexyl) phthalate; MEHP, mono(2-ethylhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; MBzP, mono-benzyl phthalate; MCPP, mono3-carboxypropyl phthalate; MEP, monoethyl phthalate; MiBP, mono-isobutyl phthalate; MBP, mono-n-butyl phthalate practical. The greater precision of findings among normal-weight girls may arise from better estimates of exposure and outcome in nonoverweight children. Overweight may compromise assessments of pubertal stage, particularly early breast stages, and could lead to different levels of exposure biomarkers, for a number of reasons. In our study, inter-examiner error was not greater for overweight girls . Statistical issues may also compromise precision among overweight girls, as there are differences in race, site and caregiver education by BMI% , and there are fewer overweight than normalweight girls. We observed associations of high-MWP with age at PH2 (pubarche) but not B2-age, which may be consistent with an antiandrogen hypothesis, as androgens are more closely tied to pubic hair than breast development (Mouritsen et al., 2013a) . That high-MWP but not low-MWP shows a relationship with age at PH2 may be attributed to several factors. First, high-MWP exposures may be less variable over time, due to sources in the indoor environment and the diet, for example (Adibi et al., 2008) , than exposures to low-MWP which may change with habits that accompany age and weight-gain, reasons that were noted by others (Frederiksen et al., 2012) . High-and low-MWP also have different relationships with BMI in our data and in a previous report (Teitelbaum et al., 2008) . Finally, high-MWP may be more anti-androgenic than the low-MWP; this is suggested by the borderline association of MBP, which is included in the low-MWP group, with PH2 but not B2. MBP is the prototypical anti-androgen, and MEP in toxicologic studies is inactive (NSF, 2008) .
Context of other research in children
Two studies since 2010 have had similar findings with regard to phthalate exposure and puberty in girls. In addition to this report and our earlier cross-sectional report of this cohort , a European cross-sectional study with high-MWP metabolite concentrations similar to those in our study detected delayed PH2 (4.8 months for SDEHP fourth versus first quartile, unadjusted; Frederiksen et al., 2012) . As in our findings, this study found earlier B2 and PH2 with MEP (not significant) and significant correlations of MEP with ages at stages 1 -4 for B2 and PH2 (highest MEP in stage 4 but lowest high-MWP in stage 4; unadjusted). A study of 84 girls by the European group found inverse relationships between urinary phthalate biomarkers and adrenal androgens, but no associations with pubertal timing possibly because of sample size (Mouritsen et al., 2013b) . A few other reports of phthalates and earlier puberty were flawed because they used a blood matrix to assess exposure which likely reflects contamination of blood specimens by exogenous phthalates [see references in Wolff and Swan (2010) ; Calafat et al. (2013) ; Engel and Wolff (2013) ].
The magnitude of the delay in age at PH2 of 8.5 months in our findings is similar to several reports that examined hormonally active exposures in HRs were computed using Cox proportional hazard models that included quintiles based on mg/g creatinine cutpoints. Adjusted models further added child race, caregiver education, child BMI percentile and study site. Interactions were assessed using BMI percentile (,85 or ≥85%) times the exposure variable (log e -mg/l or quintiles). Median ages by quintiles were determined from the survivor function of the adjusted model, evaluated at reference values of covariates.
children, but 8.5 months is less than reported differences in pubertal ages with regard to BMI and race. For example, in our study group whites are older than blacks in age at B2 by 11 months, and obese girls are younger at B2 by 19 months than normal-weight girls (1.6 year, 95th versus ,50th%; Biro et al., 2013) . The age at menarche difference for blacks versus whites has been 6 months for several decades [e.g. 12 versus 12.5 year; (Biro and Wolff, 2011)] . Various other environmental exposures have also been associated with later puberty, including perfluorochemicals and phytoestrogens; however, puberty was earlier in relation to polybrominated biphenyl (PBB) exposure measured perinatally using biomarkers (see references in Biro and Wolff, 2011; Lopez-Espinosa et al., 2011; Mervish et al., 2013) . Following environmental exposure to lead (Pb), boys were older at puberty by 6-8 months , and girls with higher Pb exposure were 4 months older for B2 and PH2 (Selevan et al., 2003) . Like our study, investigations of Pb in boys and PBBs in girls were longitudinal so that exposure was measured well before pubertal development (Blanck et al., 2000; Hauser et al., 2008) . Simultaneous modeling of six environmental biomarkers in relation to age at menarche, had expected associations for estrogenic PCBs and lead (earlier and later age, respectively) in a small crosssectional study (Denham et al., 2005) . Yet effects were similar to the six single-chemical models. In an evaluation of phthalate toxicity, a scientific panel recommended that various phthalate exposures should be combined (NSF, 2008) , as we attempted to do in our summed concentrations, but combinations also should include other chemicals with similar activity, such as anti-androgenic agents not necessarily environmental in origin. Therefore, appropriate methods to incorporate phthalates into multiple exposure models is a needed next step.
Of note, many of the findings listed above for hormonally active chemicals reveal delayed, rather than earlier, onset of puberty. Perhaps detection of earlier puberty caused by hormonally active chemicals is masked by the stronger influence of BMI at earlier than at later ages of puberty. If so, would such agents more likely act as estrogen agonists than antagonists? Associations of perinatal PBB and soy exposures with earlier puberty in girls may have been detectable because exposure was measured in a susceptible window or because it was measured before the initial rise in childhood BMI that precedes pubertal onset in girls (Karaolis-Danckert et al., 2009; Adgent et al., 2012) . Therefore, an important future question is to explain whether pubertal timing can be accelerated or delayed due to environmental exposures at earlier or later ages and whether childhood exposure increments perinatal exposure effects.
Laboratory research in rodents is consistent with our findings (Salazar et al., 2004; Grande et al., 2006) , but it also supports both later and earlier female puberty following phthalate treatment (Ashby et al., 1997; Ma et al., 2006) , inconsistencies that may reflect dosage amount, route and timing. The strongest biologic evidence regarding phthalate toxicity is for anti-androgenicity in male rodents, but delayed vaginal opening and other signs of reproductive dysfunction have been seen in female rats for several exposure windows; for example, later vaginal opening followed prepubertal administration of DEHP (Grande et al., 2006) . Notably, nipple inversion has been observed in rats exposed prenatally, both male and female, a phenomenon characterized as 'feminization' (Foster, 2006; McKee et al., 2006) . Experimentally, phthalate monoester metabolites disrupt androgen action by non-androgen receptor mechanisms, which include the peroxisome proliferator-activated receptor family for which they may be agonists or antagonists. These pathways may reduce or increase obesogenesis through complex mechanisms that control lipid and steroid metabolism as well as neuroendocrine function (Grun and Blumberg, 2009 ).
Limitations and strengths of this research
Strengths of this investigation include a longitudinal design, wide ranges of both exposures and child characteristics, including three geographical sites and a large sample size for this kind of study. A limitation is that environmental biomarkers measured in this study represent only a single point during the peripubertal window. Earlier exposures may be more influential because younger children are more susceptible or because the mechanisms governing development operate at younger ages (e.g. prenatal imprinting). There is also concern that a single biomarker measurement is not a reliable indicator of the critical window of exposure. However, our criteria for selecting biomarkers for this research project included having an adequate range of detectable biomarker concentrations (Wolff et al., 2007) and reliability over a reasonable period of time, e.g. 6-12 months' exposure in children this age or pregnant women (Teitelbaum et al., 2008; Braun et al., 2012) . Additional directions of interest are to evaluate multiple exposures, including incorporating weighting factors for relative toxicity and other developmental end-points including menarche.
We considered various confounding factors in detail, because of collinearity of BMI and the demographic covariates, but none of these factors materially altered our findings. It is of interest that two crosssectional studies, including our own earlier analysis of this sample at baseline, found similar associations. There are some concerns about using Figure 1 Survival analysis of age at PH2 jointly by BMI% (,85% normal, ≥85% overweight + obese) and the molar sum of the concentrations of di(2-ethylhexyl) phthalate urinary metabolites (SDEHP) expressed as quintiles (fifth quintile median ¼ 510 mg/g creatinine and first ¼ 59 mg/g creatinine) based on Cox proportional hazards model, calculated for the average or reference values of the covariates in the study. Predicted median ages between the fifth and first quintiles differed by 9.5 months for normal weight (P ¼ 0.013) and 6.5 months for overweight girls (P ¼ 0.617; adjusted for covariates, see Table III). creatinine-corrected biomarker concentrations to normalize urine concentration. However, in the models for continuous variables, we adjusted separately for creatinine by including it in the model with the uncorrected value (mg/l), and the model estimates were quite consistent with those from quintiles based on creatinine-corrected values (mg/g creatinine), both showing a strong linear trend. Creatinine correction did not create any outliers for the distribution of quintiles, for example, compared with the uncorrected values. We did not measure specific gravity in our samples, an alternate way of dilution normalization (Hauser et al., 2004 ); yet specific gravity and creatinine are closely correlated in many reports. There is likely some error in the pubertal stage assessment, but inter-rater agreement was satisfactory in this study. The exposure measure (urinary metabolites) also has some misclassification, for example, due to temporality because it is a one-time measure within ,5 years of pubertal onset, but errors in exposure and outcome are likely to be non-differential. There is also the possibility that some associations are due to chance; in particular, the results for MBzP and age at B2 differ from results for other phthalate metabolites. Yet an argument can be made that MBzP has certain enhanced biologic potential, as seen in other studies (Just et al., 2012) .
Summary
Phthalate exposures are highly prevalent in the environment, and children's absorbed levels are higher than adults (CDC, 2009 ). More than 10% of the girls in our study had urinary biomarker levels totaling .2 mM, for either low-or high-MWP, a biologically relevant exposure level. Understanding the impact of phthalates on development has public health significance, and there is a need to integrate lifetime exposures, especially prenatal through infancy where susceptibility to exogenous influences may be greatest. Key questions are whether childhood exposure adds to earlier life insults or acts alone, as well as how variable phthalate exposures might be over early life. There is a need to move beyond the examination of single phthalate exposures or even groupings of similar phthalates (as we have done in this analysis) toward considering combinations of chemicals where a composite mixture may act or compete in the hormonal trajectory of maturation. Relevant neuroendocrine and hormonal mechanisms also remain to be elucidated, especially with a view to how effects vary with age at exposure. Methodologic questions include whether environmental agents are more likely to be detectable for delayed rather than early puberty; also whether the magnitude of such effects are likely to be small, requiring adequate statistical power and analytic models. This research adds to the growing knowledge that phthalates may interfere with development, including genital and neurologic in addition to pubertal maturation.
